July 3 Incyte Corp

* Japan ministry of health, labor and welfare (mhlw) grants
marketing approval for olumiant® (baricitinib) for the treatment
of rheumatoid arthritis

* Incyte- ‍japan marketing authorization of olumiant
triggers $15 million milestone payment from lilly to co, which
co expects to recognize, in full,in q3 2017​
Source text for Eikon:
Further company coverage: